Antimicrobial Agents and Chemotherapy · 2016 · 40 citations · 25 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacotherapyInfection PreventionMedical MicrobiologyAntimicrobial BiomaterialsAntimicrobial TherapyBiofilm Formation In InfectionBiofilm-associated PathogenesisBiofilm-associated ResistanceUrinary Tract InfectionsAntibiotic-loaded ImplantsAntimicrobial Catheter CoatingsBiofilm InhibitorsBiofilm-associated InfectionsBiofilm-disrupting AgentsBiomaterial UseCatheter-associated BiofilmsCatheter-associated Urinary Tract Infections
ABSTRACT Pseudomonas aeruginosa is a multifaceted pathogen causing a variety of biofilm-mediated infections, including catheter-associated urinary tract infections (CAUTIs). The high prevalence of CAUTIs in hospitals, their clinical manifestations, such as urethritis, cystitis, pyelonephritis, meningitis, urosepsis, and death, and the associated economic challenges underscore the need for management of these infections. Biomaterial modification of urinary catheters with two drugs seems an interesting approach to combat CAUTIs by inhibiting biofilm. Previously, we demonstrated the in vitro efficacy of urinary catheters impregnated with azithromycin (AZM) and ciprofloxacin (CIP) against P. aeruginosa . Here, we report how these coated catheters impact the course of CAUTI induced by P. aeruginosa in a murine model. CAUTI was established in female LACA mice with uncoated or AZM-CIP-coated silicone implants in the bladder, followed by transurethral inoculation of 10 8 CFU/ml of biofilm cells of P. aeruginosa PAO1. AZM-CIP-coated implants (i) prevented biofilm formation on the implant's surface ( P ≤ 0.01), (ii) restricted bacterial colonization in the bladder and kidney ( P < 0.0001), (iii) averted bacteriuria ( P < 0.0001), and (iv) exhibited no major histopathological changes for 28 days in comparison to uncoated implants, which showed persistent CAUTI. Antibiotic implants also overcame implant-mediated inflammation, as characterized by trivial levels of inflammatory markers such as malondialdehyde ( P < 0.001), myeloperoxidase ( P < 0.05), reactive oxygen species ( P ≤ 0.001), and reactive nitrogen intermediates ( P < 0.01) in comparison to those in uncoated implants. Further, AZM-CIP-coated implants showed immunomodulation by manipulating the release of inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and IL-10 to the benefit of the host. Overall, the study demonstrates long-term in vivo effectiveness of AZM-CIP-impregnated catheters, which may possibly be a key to success in preventing CAUTIs.
25
Thomas M. Hooton, Suzanne Bradley, Diana D. Cardenas et al. · Clinical Infectious Diseases · 2010 · 2.1K citations · Full text
Public Health, Infectious Disease Control, Infectious Diseases +16
Nadine Hoffmann, Baoleri Lee, Morten Hentzer et al. · Antimicrobial Agents and Chemotherapy · 2007 · 257 citations · Full text
Avijit Hazra, Sugata Dasgupta, Soumi Das et al. · Indian Journal of Critical Care Medicine · 2015 · 190 citations · Full text
Veterinary Medicine, Infectious Diseases, Hospital Medicine +16